Reasons for producing guidelines on anemia of chronic renal failure: dialysis outcome quality initiative of the National Kidney Foundation

Citation
G. Triolo et al., Reasons for producing guidelines on anemia of chronic renal failure: dialysis outcome quality initiative of the National Kidney Foundation, INT J ARTIF, 21(11), 1998, pp. 751-756
Citations number
19
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology
Journal title
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
ISSN journal
03913988 → ACNP
Volume
21
Issue
11
Year of publication
1998
Pages
751 - 756
Database
ISI
SICI code
0391-3988(199811)21:11<751:RFPGOA>2.0.ZU;2-N
Abstract
Guidelines for the treatment of anemia in chronic renal failure (CRF) patie nts were recently published by NKF-DOQI. The background was provided by the fact that anemia in CRF patients fulfills all the criteria requested for t he outlining of guidelines. In fact: 1) anemia is a clinically relevant pro blem for CRF patients; 2) it may be prevented by adequate erythropoietin (E PO) therapy; 3) a great variability in its management exists, not only conc erning the optimal hematocrit (HCT) level, but also the treatment schedule as well as iron supplementation. More than eight hundred forty five scienti fic articles were retrieved in full text, eventually leading to 530 structu rally reviewed papers (349 cited in the final text) thus providing the basi s for the strength of recommendations (evidence or opinions): all topics we re subdivided into 7 main issues (diagnostic and therapeutic). Main results were the following: HCT, hemoglobin (Hb), red blood cell, serum iron bindi ng capacity, percent transferrin saturation (TSAT) and serum ferritin (FERR ), to evaluate the degree of anemia and iron status; HCT 33 to 36% and Hb 1 1 to 12 g/dl as possible target levels; TSAT >20% and FERR >100 ug/dl as ac ceptable lower values for iron status; oral iron administration not <200 mg /day of elemental iron and intravenous iron 50-100 mg/week or 500-100 mg/mo nth (for patients on predialysis or peritoneal dialysis) as therapeutic sch edules; subcutaneous route for EPO administration at 80-120 U/kg body weigh t/week as starting doses. Some issues may be debatable, such as, the undere stimation of dialysis efficacy among the causes of inadequate response to E PO as well as the risk of thrombosis among the possible side effects of EPO therapy, or the lack of recommendation for upper limits of FERR values. Ho wever, this exhaustive study is an important demonstration of efforts to im prove the quality of care in CRF patients.